MX367855B - Inhibidores novedosos. - Google Patents
Inhibidores novedosos.Info
- Publication number
- MX367855B MX367855B MX2015012630A MX2015012630A MX367855B MX 367855 B MX367855 B MX 367855B MX 2015012630 A MX2015012630 A MX 2015012630A MX 2015012630 A MX2015012630 A MX 2015012630A MX 367855 B MX367855 B MX 367855B
- Authority
- MX
- Mexico
- Prior art keywords
- pyroglutamic acid
- intramolecular cyclization
- novel inhibitors
- inhibitors
- under liberation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
Abstract
La invención se refiere a un compuesto de fórmula (I) o a una sal farmacéuticamente aceptable, solvato o polimorfo del mismo, incluyendo todos los tautómeros y estereoisómeros del mismo, en donde R1, R2, R3, R4 y R5 son como se define en la presente, como inhibidores de glutaminil ciclasa (QC, EC 2.3.2.5). La QC cataliza la ciclación intramolecular de los residuos de glutamina N-terminales en ácido piroglutámico (5-oxo-prolilo, pGlu*) bajo la liberación de amoníaco, y la ciclación intramolecular de los residuos de glutamato N-terminales en ácido piroglutámico bajo la liberación de agua.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361790604P | 2013-03-15 | 2013-03-15 | |
| PCT/EP2014/055106 WO2014140279A1 (en) | 2013-03-15 | 2014-03-14 | Novel inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015012630A MX2015012630A (es) | 2016-07-06 |
| MX367855B true MX367855B (es) | 2019-09-09 |
Family
ID=50434164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015012630A MX367855B (es) | 2013-03-15 | 2014-03-14 | Inhibidores novedosos. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9512115B2 (es) |
| EP (1) | EP2970235B1 (es) |
| JP (1) | JP6454651B2 (es) |
| KR (2) | KR102279084B1 (es) |
| CN (2) | CN108218849B (es) |
| AU (1) | AU2014230249B2 (es) |
| CA (1) | CA2904465C (es) |
| DK (1) | DK2970235T3 (es) |
| EA (1) | EA029451B1 (es) |
| ES (1) | ES2750645T3 (es) |
| HK (1) | HK1216531A1 (es) |
| IL (1) | IL240693B (es) |
| MX (1) | MX367855B (es) |
| NZ (1) | NZ712352A (es) |
| PL (1) | PL2970235T3 (es) |
| SG (1) | SG11201506609VA (es) |
| WO (1) | WO2014140279A1 (es) |
| ZA (1) | ZA201506156B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170363645A1 (en) | 2014-12-19 | 2017-12-21 | Probiodrug Ag | Novel Method for the Detection of pGlu-Abeta Peptides |
| CN105152977B (zh) * | 2015-09-28 | 2017-06-23 | 西南大学 | D‑对羟基苯甘氨酸衍生物及其制备方法和应用 |
| WO2019010491A1 (en) * | 2017-07-07 | 2019-01-10 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS |
| EP3747437A1 (en) | 2017-07-24 | 2020-12-09 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| EP3521308B1 (en) | 2018-01-31 | 2024-03-13 | Vivoryon Therapeutics N.V. | Humanized and de-immunized antibodies |
| JP7301862B2 (ja) | 2018-02-23 | 2023-07-03 | フラウンホーファー－ゲゼルシャフト ツル フェルデルング デル アンゲヴァンテン フォルシュング エー ファウ | 歯周病及び関連疾患の治療に用いる細菌性グルタミニルシクラーゼの新規阻害剤 |
| TWI715156B (zh) * | 2018-08-31 | 2021-01-01 | 財團法人國家衛生研究院 | 苯并咪唑化合物及其用於治療阿茲海默症或亨丁頓氏症之用途 |
| CN111333496B (zh) * | 2020-05-02 | 2023-10-13 | 武汉诺安药业有限公司 | 一种阿达帕林的制备方法 |
| CN112500361B (zh) * | 2020-12-27 | 2023-05-12 | 甘肃瀚聚药业有限公司 | 一种(s)-4-苯基-2-恶唑烷酮的制备方法 |
| CN112939797A (zh) * | 2021-02-03 | 2021-06-11 | 山东邹平大展新材料有限公司 | 一种法匹拉韦中间体2-胺基丙二酰胺的制备方法 |
| AU2022203580A1 (en) * | 2021-09-17 | 2023-04-06 | Academia Sinica | Methods of Increasing Cell Phagocytosis |
| CN114295746A (zh) * | 2021-12-27 | 2022-04-08 | 卓和药业集团股份有限公司 | 一种匹伐他汀钙的分析检测方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA009291B1 (ru) * | 2003-05-05 | 2007-12-28 | Пробиодруг Аг | Применение эффекторов глутаминил- и глутаматциклаз |
| WO2008055950A1 (en) * | 2006-11-09 | 2008-05-15 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
| SG193828A1 (en) * | 2008-09-04 | 2013-10-30 | Probiodrug Ag | Novel inhibitors |
| US8486940B2 (en) * | 2009-09-11 | 2013-07-16 | Probiodrug Ag | Inhibitors |
| AU2012228236B2 (en) | 2011-03-16 | 2016-10-27 | Vivoryon Therapeutics N.V. | Diagnostic antibody assay |
| EP2714098A1 (en) | 2011-05-27 | 2014-04-09 | Probiodrug AG | Radiolabelled glutaminyl cyclase inhibitors |
-
2014
- 2014-03-14 CA CA2904465A patent/CA2904465C/en active Active
- 2014-03-14 EP EP14714949.6A patent/EP2970235B1/en active Active
- 2014-03-14 AU AU2014230249A patent/AU2014230249B2/en active Active
- 2014-03-14 KR KR1020157028379A patent/KR102279084B1/ko active IP Right Grant
- 2014-03-14 JP JP2015562197A patent/JP6454651B2/ja active Active
- 2014-03-14 SG SG11201506609VA patent/SG11201506609VA/en unknown
- 2014-03-14 EA EA201500930A patent/EA029451B1/ru unknown
- 2014-03-14 WO PCT/EP2014/055106 patent/WO2014140279A1/en active Application Filing
- 2014-03-14 KR KR1020217021968A patent/KR20210091830A/ko not_active Application Discontinuation
- 2014-03-14 PL PL14714949T patent/PL2970235T3/pl unknown
- 2014-03-14 US US14/775,785 patent/US9512115B2/en active Active
- 2014-03-14 CN CN201810142065.8A patent/CN108218849B/zh active Active
- 2014-03-14 DK DK14714949.6T patent/DK2970235T3/da active
- 2014-03-14 ES ES14714949T patent/ES2750645T3/es active Active
- 2014-03-14 NZ NZ712352A patent/NZ712352A/en unknown
- 2014-03-14 MX MX2015012630A patent/MX367855B/es active IP Right Grant
- 2014-03-14 CN CN201480027433.4A patent/CN105263927B/zh active Active
-
2015
- 2015-08-20 IL IL240693A patent/IL240693B/en active IP Right Grant
- 2015-08-24 ZA ZA2015/06156A patent/ZA201506156B/en unknown
-
2016
- 2016-04-20 HK HK16104524.9A patent/HK1216531A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014140279A1 (en) | 2014-09-18 |
| HK1216531A1 (zh) | 2016-11-18 |
| CA2904465C (en) | 2021-07-13 |
| IL240693A0 (en) | 2015-10-29 |
| EP2970235A1 (en) | 2016-01-20 |
| EP2970235B1 (en) | 2019-06-19 |
| MX2015012630A (es) | 2016-07-06 |
| CN108218849A (zh) | 2018-06-29 |
| ZA201506156B (en) | 2017-11-29 |
| ES2750645T3 (es) | 2020-03-26 |
| KR20150128928A (ko) | 2015-11-18 |
| CA2904465A1 (en) | 2014-09-18 |
| KR20210091830A (ko) | 2021-07-22 |
| CN105263927A (zh) | 2016-01-20 |
| BR112015023454A2 (pt) | 2017-12-05 |
| PL2970235T3 (pl) | 2019-12-31 |
| JP6454651B2 (ja) | 2019-01-23 |
| SG11201506609VA (en) | 2015-09-29 |
| NZ712352A (en) | 2016-07-29 |
| US9512115B2 (en) | 2016-12-06 |
| JP2016513632A (ja) | 2016-05-16 |
| KR102279084B1 (ko) | 2021-07-20 |
| IL240693B (en) | 2019-09-26 |
| EA029451B1 (ru) | 2018-03-30 |
| CN105263927B (zh) | 2019-03-15 |
| DK2970235T3 (da) | 2019-09-23 |
| US20160031869A1 (en) | 2016-02-04 |
| EA201500930A1 (ru) | 2016-04-29 |
| CN108218849B (zh) | 2022-03-01 |
| AU2014230249A1 (en) | 2015-10-08 |
| AU2014230249B2 (en) | 2016-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ712352A (en) | Novel inhibitors of glutaminyl cyclase | |
| PH12017502090A1 (en) | Heterocyclic amides as kinase inhibitors | |
| PH12017500408A1 (en) | Heteroaryl compunds as btk inhibitors and uses thereof | |
| SG178953A1 (en) | Heterocylcic derivatives as inhibitors of glutaminyl cyclase | |
| MX2018002986A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos. | |
| NZ739676A (en) | Heteroaryl compounds as irak inhibitors and uses thereof | |
| EA201201275A1 (ru) | Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5) | |
| TN2013000253A1 (en) | Bicyclo[3.2.1]octyl amide derivatives and uses of same | |
| WO2011107530A3 (en) | Inhibitors of glutaminyl cyclase | |
| TN2011000400A1 (en) | Inhibitors of beta-secretase | |
| MX2014001879A (es) | Aminoquinazolinas como inhibidores de quinasa. | |
| IN2015MN00405A (es) | ||
| MX341456B (es) | Amino-quinolinas como inhibidores de cinasa. | |
| MX2016007861A (es) | Compuestos de ácido dimetilbenzoico. | |
| JO3318B1 (ar) | مثبطات bace | |
| EA024194B8 (ru) | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы | |
| MX2017009624A (es) | Macrociclos de piridazinona como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos. | |
| NZ703714A (en) | 2-aminopyrazine derivatives as csf-1 r kinase inhibitors | |
| MD20160105A2 (ro) | 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide | |
| NZ605558A (en) | Benzamide derivatives and their use as hsp90 inhibitors | |
| MX368496B (es) | Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp. | |
| AU2015292632B2 (en) | Aldosterone synthase inhibitors | |
| WO2011131748A3 (en) | Benzimidazole derivatives as inhibitors of glutaminyl cyclase | |
| MX359399B (es) | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. | |
| MD20150103A2 (ro) | Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |